Truist Securities analyst Robyn Karnauskas downgrades MEI Pharma (NASDAQ:MEIP) from Buy to Hold.
Mizuho Maintains Buy on Alkermes, Lowers Price Target to $34
Mizuho analyst Vamil Divan maintains Alkermes (NASDAQ:ALKS) with a Buy and lowers the price target from $36 to $34.